David Change News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share The University of Glasgow will play a key role in a new pan European consortium, using artificial intelligence to improve treatments for pancreatic cancer. PANCAIM will improve treatment for pancreatic cancer patients, utilising tools such as artificial intelligence, integrated genomics and medical imaging. Dr David Chang from the Institute of Cancer Sciences will lead the work for the University of Glasgow, and will bring a wealth of experience in precision medicine in pancreatic cancer. Pancreatic Cancer PANCAIM is a four year Horizon 2020 funded project, and is a partnership between the University of Glasgow, the Karolinska Institute, Radboud University in the Netherlands, the Spanish National Cancer Research Centre, Oslo University Hospital, and industry partners, Siemens, SMEs Collective Minds Radiology, The Hyve and is project managed by Amires.

Siemens healthineersDavid changKarolinska instituteInstitute of cancer sciencesEuropean commission horizonUniversity of glasgowSpanish national cancer research centreRadboud universityOslo university hospitalCancer sciencesCollective minds radiologyDavid changePan europeanடேவிட் சாங்நிறுவனம் ஆஃப் புற்றுநோய் அறிவியல்ஐரோப்பிய தரகு அடிவானம்